Exceptional 30-year survival of a patient with multiple myeloma – quality of life and management of disease-related symptoms
- 1 January 2024
- journal article
- research article
- Published by Termedia Sp. z.o.o. in Palliative Medicine
- Vol. 16 (3) , 200-204
Abstract
Multiple myeloma (MM) is a chronic plasma cell malignancy with a median survival of about 8–10 years. Despite the development of many new drugs in recent years, disease recurrence is inevitable. The current critical unmet need is the management of heavily pretreated patients with refractory MM....Keywords
This publication has 17 references indexed in Scilit:
- Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA: A Cancer Journal for Clinicians, 2024
- Isatuximab: First ApprovalDrugs, 2020
- Supportive Care in Multiple MyelomaCurrent Hematologic Malignancy Reports, 2020
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyThe Lancet, 2019
- Quality of life in multiple myeloma: considerations and recommendationsExpert Review of Hematology, 2019
- Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case reportBMC Cancer, 2017
- The Diagnosis and Treatment of Multiple MyelomaDeutsches Ärzteblatt international, 2016
- Long-term survival consequent on the abscopal effect in a patient with multiple myelomaBMJ Case Reports, 2016
- Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the LiteratureCase Reports in Oncology, 2015
- Improved long-term survival in multiple myeloma up to the age of 80 yearsLeukemia, 2014